Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

被引：2

作者：

Nitz, Ulrike ^{[1
,2
]}

Gluz, Oleg ^{[1
,2
]}

Kates, Ronald E. ^{[1
]}

Hofmann, Daniel ^{[1
]}

Kreipe, Hans H. ^{[3
]}

Christgen, Matthias ^{[3
]}

Shak, Steve ^{[4
]}

Clemens, Michael ^{[5
]}

Kraemer, Stefan

Aktas, Bahriye ^{[6
]}

Kuemmel, Sherko ^{[7
]}

Reimer, Toralf ^{[8
]}

Kusche, Manfred ^{[9
]}

Heyl, Volker ^{[10
]}

Lorenz-Salehi, Fatemah ^{[11
]}

Just, Marianne ^{[12
]}

Liedtke, Cornelia ^{[1
,13
]}

Wuerstlein, Rachel ^{[1
,14
]}

Harbeck, Nadia ^{[1
,14
]}

机构：

[1] West German Study Grp, Dusseldorf, Germany

[2] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany

[3] Hannover Med Sch, Inst Pathol, Hannover, Germany

[4] Genom Hlth Inc, Redwood City, CA USA

[5] Breast Ctr, Mutterhaus Borromaerinnen, Trier, Germany

[6] Univ Clin Essen, Women Clin, Essen, Germany

[7] Clin Essen Mitte, Women Clin, Essen, Germany

[8] Clin Suedstadt, Rostock, Germany

[9] Marien Hosp Aachen, Women Clin, Aachen, Germany

[10] Asklepios Paulinen Clin, Wiesbaden, Germany

[11] Dr Horst Schmidt Clin, Women Clin, Wiesbaden, Germany

[12] Oncol Practice, Bielefeld, Germany

[13] Univ Clin Schleswig Holstein, Kiel, Germany

[14] LMU, Univ Clin Grosshadern, Breast Ctr, Munich, Germany

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.SABCS14-P4-11-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-11-01

引用

页数：2

共 36 条

[1] Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial
Gluz, O.
Kreipe, H. H.
Kates, R. E.
Christgen, M.
Liedtke, C.
Shak, S.
Clemens, M.
Salem, M.
Liedtke, B.
Aktas, B.
Markmann, S.
Uleer, C.
Augustin, D.
Thomssen, C.
Nitz, U.
Harbeck, N.
CANCER RESEARCH, 2012, 72
[2] Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial
Gluz, Oleg
Kreipe, Hans Heinrich
Christgen, Matthias
Degenhardt, Tom
Kates, Ronald E.
Liedtke, Cornelia
Shak, Steven
Clemens, Michael R.
Salem, Marwa
Markmann, Susanne
Liedtke, Bernd
Aktas, Bahriye
Henschen, Stephan
Pollmanns, Anke
Krabisch, Petra
Uleer, Christoph
Augustin, Doris
Thomssen, Christoph
Nitz, Ulrike
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Hormone receptor discordance between local and central pathology with RT-PCR analysis: Results from multicenter Phase III WSG-PlanB trial.
Von Schumann, Raquel
Gluz, Oleg
Nitz, Ulrike
Clemens, Michael
Luebbe, Kristina
Aktas, Bahriye
Just, Marianne
Noesselt, Thomas
Henschen, Stephan
Hackmann, John
Lorenz-Salehi, Fatemeh
Freese, Kristin
Svedman, Christer
Kates, Ronald E.
Kreipe, Hans Heinrich
Harbeck, Nadia
Liedtke, Cornelia
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] PROSPECTIVE COMPARISON OF RISK ASSESSMENT TOOLS IN EARLY BREAST CANCER: CORRELATION ANALYSIS FROM THE PHASE III WSG-PLAN B TRIAL
Gluz, O.
Kreipe, H. H.
Degenhardt, T.
Salem, M.
Kates, R. E.
Shak, S.
Svedman, C.
Liedtke, C.
Nitz, U.
Harbeck, N.
ANNALS OF ONCOLOGY, 2012, 23 : 18 - 18
[5] Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.
Giuz, O.
Kreipe, H.
Degenhardt, T.
Kates, R.
Christgen, M.
Liedtke, C.
Shak, S.
Clemens, M.
Markmann, S.
Uleer, C.
Augustin, D.
Thomssen, C.
Nitz, U.
Harbeck, N.
CANCER RESEARCH, 2011, 71
[6] Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer
Patel, Rima
Hovstadius, Malin
Kier, Melanie W.
Moshier, Erin L.
Zimmerman, Brittney S.
Cascetta, Krystal
Jaffer, Shabnam
Sparano, Joseph A.
Tiersten, Amy
CANCER, 2022, 128 (20) : 3602 - 3609
[7] Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
Gluz, Oleg
Nitz, Ulrike
Christgen, Matthias
Kates, Ronald E.
Clemens, Michael
Kraemer, Stefan
Nuding, Benno
Reimer, Toralf
Aktas, Bahriye
Kummel, Sherko
Just, Marianne
Stefek, Andrea
Lorenz-Salehi, Fatemeh
Krabisch, Petra
Liedtke, Cornelia
Svedman, Christer
Shak, Steven
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Harbeck, Nadia
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer
Gluz, O.
Nitz, U.
Christgen, M.
Kates, R.
Clemens, M.
Kraemer, S.
Nuding, B.
Aktas, B.
Kuemmel, S.
Reimer, T.
Lorenz-Salehi, F.
Krabisch, P.
Just, M.
Augustin, D.
Liedtke, C.
Svedman, C.
Shak, S.
Wuerstlein, R.
Kreipe, H.
Harbeck, N.
EUROPEAN JOURNAL OF CANCER, 2016, 57 : S6 - S6
[9] Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC).
Patel, Rima
Hovstadius, Malin
Kier, Melanie Wain
Moshier, Erin
Zimmerman, Brittney Shulman
Cascetta, Krystal Pauline
Jaffer, Shabnam
Sparano, Joseph A.
Tiersten, Amy
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2-early breast cancer (EBC): WSG PlanB trial results
Gluz, O.
Nitz, U.
Christgen, M.
Malter, W.
Clemens, M.
Reimer, T.
Nuding, B.
Aktas, B.
Stefek, A.
Ppllmanns, A.
Lorenz-Salehi, F.
Uleer, C.
Krabisch, P.
Kuemmel, S.
Liedtke, C.
Shak, S.
Kates, R.
Wurstlein, R.
Kreipe, H. H.
Harbeck, N.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 →